Serum copeptin in women with gestational diabetes mellitus: A meta-analysis

Authors

  • Yuanqi He Department of Obstetrics, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China
  • Xue Li Department of Obstetrics, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China
  • Xiaoxiao Li Department of Obstetrics, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China
  • Weiwei Cui Department of Obstetrics, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China
  • Shihong Zhang Department of Gynaecology and Obstetrics, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China

DOI:

https://doi.org/10.17305/bb.2024.10114

Keywords:

Copeptin, gestational diabetes mellitus (GDM), biomarker, serum, meta-analysis

Abstract

Previous studies have reported mixed results regarding the relationship between serum copeptin levels and gestational diabetes mellitus (GDM) risk. To address inconsistencies in prior research, this meta-analysis examines the potential link between serum copeptin levels and the risk of developing GDM. Our objective was to comprehensively evaluate this association. We systematically reviewed observational studies from Medline, Web of Science, Embase, Wanfang, and China National Knowledge Infrastructure (CNKI) databases up to October 15, 2023, employing a random-effects model to integrate the data while considering heterogeneity. This analysis incorporated 10 studies comprising 625 women with GDM and 1212 healthy pregnant controls. Our findings showed no significant difference in serum copeptin levels between women with GDM and those without (standardized mean difference [SMD] 0.01, 95% confidence interval [CI] −0.22 to 0.24, P = 0.92, I2 = 75%). Univariate meta-analysis indicated a positive correlation between the body mass index (BMI) of the participants and the outcomes (coefficient = 0.11, P = 0.002). Further subgroup analysis demonstrated that women with a mean BMI ≥ 26 kg/m2 and GDM had significantly higher serum copeptin levels compared to their non-GDM counterparts (SMD 0.31, 95% CI 0.05 to 0.57, P = 0.02, I2 = 46%). Conversely, no difference was observed in women with a BMI < 26 kg/m2 (SMD −0.23, 95% CI −0.37 to−0.09, P = 0.002, I2 = 0%, P for subgroup difference = 0.003). Variables, such as the country of study, maternal age, the timing of blood sampling, copeptin measurement methods, or GDM diagnostic criteria did not significantly affect the results. In summary, the association between serum copeptin levels and GDM risk is influenced by the BMI of pregnant women, indicating that elevated serum copeptin might be linked to GDM in individuals with a BMI ≥ 26 kg/m2.

Downloads

Download data is not yet available.
Serum copeptin in women with gestational diabetes mellitus: A meta-analysis

Downloads

Published

07-03-2024

Issue

Section

Reviews

Categories

How to Cite

1.
Serum copeptin in women with gestational diabetes mellitus: A meta-analysis. Biomol Biomed [Internet]. 2024 Mar. 7 [cited 2024 May 26];. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/10114